Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US

• DOI: 10.2147/jaa.s424055
• Publication Date: 2023-12-01T03:30:19Z
• Authors: Michael Bogart; Guillaume Germain; François Laliberté; Malena Mahendran; Mei Sheng Duh; Kristi DiRocco; Stephen G Noorduyn; Rosirene Paczkowski; Ronald Balkissoon
• Keywords: Fluticasone propionate; Dry-powder inhaler; Salmeterol; Rate ratio; Clinical endpoint

Real-world asthma control data among patients initiating fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) are limited. This study assessed rescue medication use and asthma-related exacerbations in with before after single-inhaler FF/UMEC/VI using administrative claims data.This retrospective, pre-post cohort analyzed from the IQVIA PharMetrics Plus database (September 18, 2016‒March 31, 2020). Patients aged ≥18 years that had ≥1 dispensing of 100/62.5/25 mcg (first = index date), ≥12 months continuous health insurance enrollment prior to (pre-treatment) following (post-treatment) initiation diagnosis during pre-treatment period or on date were included. The primary endpoint was number oral corticosteroid (OCS) dispensings per patient year pre- post-treatment periods. Secondary endpoints included exacerbation rates short-acting β2-agonist (SABA) use. Comparisons between periods made risk rate ratios.Overall, 890 treatment most recently dispensed controller medications inhaled corticosteroids/long-acting β2-agonists (33.5%) leukotriene modifiers (33.0%). a 29% reduction OCS (rate ratio [95% confidence interval (CI)]: 0.71 [0.65, 0.77], P < 0.001) versus pre-treatment, 23% proportion (risk CI]: 0.77 [0.73, 0.82], 0.001). Significant reductions CI]) (0.59 [0.52, 0.67], SABA (0.80 [0.74, 0.86], also observed.In this real-world study, significantly lower use, exacerbations, compared their period. These results suggest better routine clinical practice setting.